Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities

Executive Summary

The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.

You may also be interested in...

England’s Innovative Medicines Fund Needs De-Risking To Make It Work

The Innovative Medicines Fund is not delivering the ambition that was set out when it was launched in England last year, according to one UK company general manager.

BMS’ Sprycel Is Latest CDF Drug To Get NICE Clearance For Routine NHS Use

NICE has given the go-ahead for routine NHS commissioning of seven cancer drugs/indications that were listed on the Cancer Drugs Fund before it was overhauled earlier this year. A total of 35 product indications are up for reappraisal under the program.

Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven

On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts